Skip to main content

Valinor Discovery

Category: AI in Healthcare

An AI-powered biotechnology platform that generates 'Virtual Patient' models to simulate clinical trial outcomes and drug efficacy before human testing begins. Valinor Discovery was founded in 2024. The company is led by Joshua Pacini. Based in San Francisco, CA. Team size: 1-10. Total funding raised: $13.0M. Latest round: Seed ($13.0M, Dec 2025). Key investors include ["CRV","Harpoon Ventures","Amino Collective","Pelion Venture Partners"].

Founded
2024
Headquarters
San Francisco, CA
Team size
1-10
Total funding
$13.0M

Value proposition

Reduces the 90% failure rate of clinical trials by allowing drug hunters to test therapies on virtual patient profiles derived from matched multi-omics and clinical assay data, saving years of development time and millions in R&D costs.

Products and solutions

["Virtual Patient Models (Core Platform)","Patient Stratification Workflows","Hit-to-Lead Analysis Engine","Biomarker Panel Selection Tools","Latch Bio Interface (No-code compliant web portal for model access)"]

Unique value

Unlike competitors focusing on 'virtual cells' or synthetic data, Valinor creates holistic 'virtual patients' using proprietary matched datasets that link deep biological data (multi-omics) directly to actual clinical outcomes.

Target customer

Pharmaceutical companies, Biotechnology firms, and Clinical Research Organizations (CROs)

Industries served

["Biotechnology","Pharmaceuticals","Artificial Intelligence","Clinical Research"]

Technology advantage

Possesses a proprietary data moat of matched patient samples (biopsies, cellular samples) and clinical assay results, training multimodal ML models to predict physiological responses with high fidelity.

How they differentiate

Valinor differentiates by creating 'Virtual Patients' using proprietary matched multi-omics and clinical assay data (biopsies, cellular samples) to predict clinical outcomes before trials start. This contrasts with Unlearn.AI (which uses historical clinical data for statistical digital twins) and Recursion (which focuses on cellular-level phenomics/images rather than patient-level clinical translation).

Main competitors

["Unlearn.AI","Recursion","QuantHealth"]

Key partnerships

["Latch Bio (Strategic partnership for cloud infrastructure and no-code interface)","Stanford Medicine - Montgomery Lab (Collaboration on Alzheimer’s disease compound evaluation)","Helmholtz Munich - Theis Lab (Collaboration on drug perturbation prediction)"]

Notable customers

["Stanford Medicine (Montgomery Lab)","Helmholtz Munich (Theis Lab)","Latch Bio (Strategic Partner)"]

Major milestones

["Exited stealth mode in May 2025 with 'Virtual Patient' platform launch","Secured $13M Seed funding led by CRV in Dec 2025","Partnered with Latch Bio to deliver no-code compliant web portal"]

Growth metrics

Emerged from stealth in May 2025; Established strategic partnerships for data and platform delivery immediately upon launch.

Market positioning

Pre-clinical to clinical translation platform (AI-driven patient stratification)

Geographic focus

North America (San Francisco, Utah), Europe (Munich partnership)

Patents and IP

Relies on proprietary trade secret datasets and machine learning architectures; no specific public patent filings disclosed as of late 2025.

About Joshua Pacini

Founder and CEO of Valinor Discovery. Previously attended Brigham Young University.

Official website: